OnKure Therapeutics, Inc., formerly Reneo Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company focused on the discovery and development of precision medicines that target biologically validated drivers of cancers that are underserved by available therapies. Using a structure-based drug design platform, the Co. is building a robust pipeline of tumor-agnostic candidates. Co. is developing OKI-219, a selective PI3K?H1047R inhibitor, as its lead program. OKI-219 is being evaluated in a Phase I clinical trial in solid tumor patients with PI3K?H1047R mutations, including breast cancer. We show 3 historical shares outstanding datapoints in our coverage of OKUR's shares outstanding history.
Understanding the changing numbers of OKUR shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like OKUR versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching OKUR by allowing them to research OKUR shares outstanding history
as well as any other stock in our coverage universe. |
Free OKUR Email Alerts:
Video: Shares Outstanding Importance
